Jupiter Neurosciences Announces 1-for-75 Reverse Stock Split Effective August 6; Stock Down
Jupiter Neurosciences (JUNS) will implement a 1-for-75 reverse stock split effective Aug. 6, 2026, after shareholder approval on July 22. The company says it aims to raise the per-share price to regain Nasdaq minimum bid compliance. Shares fall from about 57.76M to ~770,081; no fractional shares, cash paid based on Aug. 6 close.
How this was made
The 30-second read
Why it matters
The reverse split reduces share count from about 57.76 million to about 770,081 shares and is intended to lift the per-share price above Nasdaq’s minimum bid requirement. This is a near-term trading event with potential volatility around the effective date, but the article does not introduce new efficacy, safety, or financing details.
Market read
Event-driven traders may position for split-related volatility and compliance headlines, while fundamental traders likely wait for new clinical or financing updates.
What to watch
Cash payments for fractional shares and the new CUSIP can create settlement and liquidity quirks; also, the article provides no update on pipeline timelines, so fundamental catalysts remain unchanged.
Background
Jupiter Neurosciences is a clinical-stage biopharma focused on neurological and neurodegenerative disorders, and it is attempting to restore Nasdaq compliance after trading below the minimum bid threshold.
Ticker impact
Jupiter Neurosciences approved a 1-for-75 reverse split effective Aug. 6 to regain Nasdaq minimum bid compliance, with trading split-adjusted Aug. 7.
Expect elevated volatility around Aug. 6 close and Aug. 7 split-adjusted open, with direction driven more by sentiment and compliance expectations than by fundamentals.
The article discloses the split ratio, effective date, share count reduction, and cash-in-lieu for fractional shares, which are immediate trading mechanics. It provides no new clinical or financial guidance, so fundamental repricing is less certain.
Market effects
Microcap and clinical-stage biopharma names with sub-$1 trading can see similar compliance-driven reverse split risk, increasing event-driven volatility across the group.
Primarily US-focused since the catalyst is Nasdaq minimum bid compliance.
Limited, as the event is company-specific and tied to US listing rules.
Counterpoint
The reverse split may simply be a technical fix to avoid delisting, so traders should not over-interpret it as an operational turnaround signal.
Key entities
- companyJupiter Neurosciences, Inc.
Clinical-stage biopharmaceutical company announcing a 1-for-75 reverse stock split effective Aug. 6 to regain Nasdaq minimum bid compliance.
- venue/regulatorNasdaq
Exchange whose minimum bid price requirement the company is targeting to meet.
